The Telstra and Telkom-backed enterprise messaging software provider priced its shares at the foot of the IPO's range but is in line to raise $32.5m when it floats next month.

Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.

AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.

The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.

GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.

Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

The O'Reilly Media, Deutsche Telekom and Swisscom-backed content delivery software provider floated at the top of its range and popped on its first day of trading.

Alexandria Real Estate Equities-backed Applied Therapeutics has gone public despite having to drastically cut its expectations for the offering.

Ride hailing services company Uber, backed by many corporate investors, held its long-awaited $8.1bn IPO, which was the world's largest since 2014, though many consider it a disappointment